C4 Therapeutics Inc
CCCCHealthcare|Biotechnology|USA
$4.06
-0.23 (-5.36%)
Tangible Book
$2.25
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07284758 A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | P2 | Recruiting | 100 | Open-label | Cemsidomide, Dexamethasone |
| NCT07280013 A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Multiple Myeloma (MM) | P1 | Recruiting | 60 | Open-label | Cemsidomide, Elranatamab |
| NCT04756726 Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Multiple Myeloma, Lymphoma, Non-Hodgkin's | P1 | Active | 224 | Open-label | cemsidomide, Dexamethasone Oral |
| NCT05355753 A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | Synovial Sarcoma, Soft Tissue Sarcoma | P1 | Terminated | 49 | Open-label | CFT8634 |
| NCT05668585 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | Solid Tumors, Melanoma | P1 | Completed | 89 | Open-label | CFT1946, Trametinib, Cetuximab |
| NCT06206161 Optimizing and Advancing SBIRT in Schools | Adolescent Drinking, Adolescent Substance Use | N/A | By Invite | 21,000 | RCT, Open-label | — |